Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias

Area of Science:

• Hematology
• Cancer Biology
• Molecular Oncology

Background:

• Venetoclax, a BCL-2 inhibitor, transforms leukemia treatment, but TP53-mutated leukemias can resist therapy.
• TP53 regulates apoptosis upstream of BCL-2 and MCL-1, making these proteins potential targets in TP53-dysfunctional cancers.

Purpose of the Study:

• To investigate the role of TP53 in long-term responses to BH3-mimetic drugs.
• To determine optimal therapeutic strategies for TP53-mutant leukemias.

Main Methods:

• Comparative analysis of TP53-mutant versus wild-type myeloid and lymphoid leukemias.
• Assessment of cellular responses to varying concentrations of BCL-2 and MCL-1 targeting BH3-mimetics.
• Evaluation of combined BH3-mimetic therapy efficacy.

Main Results:

• TP53-mutant leukemias outcompeted controls under sublethal BH3-mimetic treatment.
• Tumor cells with TP53 dysfunction showed increased resistance to BCL-2 or MCL-1 inhibition due to higher BAX/BAK activation thresholds.
• Combined BCL-2 and MCL-1 inhibition achieved durable leukemia suppression, overcoming TP53 mutations.

Conclusions:

• TP53 status is critical in determining long-term efficacy of BH3-mimetics, explaining varied clinical responses.
• Sufficiently lethal combination therapies are essential for maximizing outcomes in TP53-mutant leukemias.
• Sublethal BH3-mimetic regimens risk disease progression driven by emergent TP53-mutant clones.